Long lasting anti-angiogenic peptides

Details Long lasting anti-angiogenic peptides Long lasting anti-angiogenic peptides

2006-12-05

2006-12-05

Chism, B. Dell (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S019300, C514S014800, C514S015800, C514S016700, C530S329000, C530S328000, C530S327000, C435S068100

Reexamination Certificate

active

07144854

ABSTRACT:
Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.

REFERENCES:
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5733876 (1998-03-01), O'Reilly et al.
patent: 5776704 (1998-07-01), O'Reilly et al.
patent: 5792845 (1998-08-01), O'Reilly et al.
patent: 5801146 (1998-09-01), Davidson
patent: 5837682 (1998-11-01), Folkman et al.
patent: 5854221 (1998-12-01), Cao et al.
patent: 5861372 (1999-01-01), Folkman et al.
patent: 5885795 (1999-03-01), O'Reilly et al.
patent: 5945403 (1999-08-01), Folkman et al.
patent: 5972896 (1999-10-01), Davidson
patent: 5981484 (1999-11-01), Davidson
patent: 6024688 (2000-02-01), Folkman et al.
patent: 6057122 (2000-05-01), Davidson
patent: 0602290 (1994-06-01), None
patent: 9723500 (1997-07-01), None
patent: 9741824 (1997-11-01), None
patent: WO 97/41824 (1997-11-01), None
patent: 9854217 (1998-12-01), None
patent: 9900420 (1999-01-01), None
patent: 9924074 (1999-05-01), None
patent: 9924075 (1999-05-01), None
patent: 9948536 (1999-09-01), None
patent: 0004052 (2000-01-01), None
patent: 00 47729 (2000-08-01), None
patent: 0048595 (2000-08-01), None
patent: 0054796 (2000-09-01), None
patent: 0061179 (2000-10-01), None
patent: 00/76550 (2000-12-01), None
patent: 00/76551 (2000-12-01), None
Dermer, G.B., 1994, Bio/Technology, vol. 12, p. 320.
Cancer Research, 1986, 46, 467-473.
J. Natl. Cancer Institute, 1989, 82, 4-6.
Anti-Cancer Drugs, 1997, 8, 677-685.
U.S. Appl. No. 09/623,543, filed Sep. 2000, Bridon et al.
Bailey, P. D., (1990)An Introduction to Peptide Chemistry,John Wiley & Sons, Inc., New York, NY, pp. 132-133.
Dermer, Gerard B., (Mar. 1994) “Another Anniversary for the War on Cancer,” Bio/Technology, 12: 320.
Humphries, Martin J. et al., (1994) “Conjugation of Synthetic peptides to carrier proteins for cell adhesion studies,” J. Tissue Culture Methods, 16: 239-242.
Peeters, J. M. et al., (1989) “Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates,” J. Immunol. Methods, 120: 133-143.
Pietersz, Geoffrey A., (1990) “The Linkage of Cytotoxic Drugs to Monoclonal Antibodies for the Treatment of Cancer,” Bioconjugate Chemistry, 1(2): 89-94.
Yeh, Patrice et al., (Mar. 1992) “Design of yeast-secreted albumin derivatives for human therapy: Biological and antiviral properties of serum albumin-CD4 genetic conjugate,” Proc. Natl. Acad. Sci. USA, 89: 1904-1908.

Affiliated with

Also associated with

Rating

Long lasting anti-angiogenic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Long lasting anti-angiogenic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long lasting anti-angiogenic peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3698380